Novel and sensitive reversed-phase high-pressure liquid chromatography method with electrochemical detection for the simultaneous and fast determination of eight biogenic amines and metabolites in human brain tissue

Journal of Chromatography A

Volumn 1353, Issue , 2014, Pages 28-39

  Van Dam, Debby ^a   Vermeiren, Yannick ^a   Aerts, Tony ^a   De Deyn, Peter Paul ^a,b,c  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Biogenic amines; HPLC ECD; Human brain tissue; Method optimization; Method validation

Indexed keywords

BIOMOLECULES; BRAIN; CHEMICAL DETECTION; DRUG PRODUCTS; ELECTROCHEMICAL SENSORS; HIGH PRESSURE LIQUID CHROMATOGRAPHY; ION CHROMATOGRAPHY; METABOLITES; REDUCTION; TISSUE;

3 ,4-DIHYDROXYPHENYLACETIC ACIDS; BIOGENIC AMINES; ELECTROCHEMICAL DETECTION; FRACTIONAL FACTORIAL EXPERIMENTAL DESIGN; HPLC-ECD; HUMAN BRAIN; METHOD VALIDATIONS; ROBUST ANALYTICAL METHODS;

AMINES;

3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXY 3 METHOXYPHENYLETHYLENE GLYCOL; 5 HYDROXYINDOLEACETIC ACID; ADRENALIN; BIOGENIC AMINE; DOPAMINE; HOMOVANILLIC ACID; METHANOL; NORADRENALIN; SEROTONIN;

ARTICLE; BRAIN TISSUE; COLUMN TEMPERATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DILUTION; ELECTRIC POTENTIAL; ELECTROCHEMICAL DETECTION; EXPERIMENTAL DESIGN; FACTORIAL ANALYSIS; HUMAN; HUMAN TISSUE; ION PAIR CHROMATOGRAPHY; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MEASUREMENT ACCURACY; MOBILE PHASE; PH; PHYSICAL PARAMETERS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; REACTION TIME; REPRODUCIBILITY; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; ANIMAL; BRAIN; BRAIN LEVEL; ELECTROCHEMICAL ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; PROCEDURES; REVERSED PHASE LIQUID CHROMATOGRAPHY; TIME;

ANIMALS; BIOGENIC AMINES; BRAIN; BRAIN CHEMISTRY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, REVERSE-PHASE; ELECTROCHEMICAL TECHNIQUES; HUMANS; TIME FACTORS;

EID: 84903174678     PISSN: 00219673     EISSN: 18733778     Source Type: Journal    
DOI: 10.1016/j.chroma.2014.05.004     Document Type: Article

References (28)

1. Tarazi F.I., Kaufman M.J. Neural principles of neurological and psychiatric disorders. Current Clinical Neurology: Neurological and Psychiatric Disorders: From Bench to Bedside 2005, 3. Humana Press Inc, Totowa, NJ. 10.1385/1-59259-856-0:003. F.I. Tarazi, J.A. Schetz (Eds.).
2. Schetz J.A. Pharmacotherapeutic principles of neurological and psychiatric disorders. Current Clinical Neurology: Neurological and Psychiatric Disorders: From Bench to Bedside 2005, 29. Humana Press Inc, Totowa, NJ. 10.1385/1-59259-856-0:029. F.I. Tarazi, J.A. Schetz (Eds.).
3. Peaston R.T., Weinkove C. Ann. Clin. Biochem. 2004, 41(Pt 1):17. 10.1258/000456304322664663.
4. Yoshitake T., Kehr J., Todoroki K., Nohta H., Yamaguchi M. Biomed. Chromatogr. 2006, 20(3):267. 10.1002/bmc.560.
5. Bicker J., Fortuna A., Alves G., Falcão A. Anal. Chim. Acta. 2013, 768:12. 10.1016/j.aca.2012.12.030.
6. Wagner J., Palfreyman M., Zraika M. J. Chromatogr. 1979, 164(1):41. 10.1016/S0378-4347(00)81570-4.
7. Tusell J.M., Suñol C., Artigas F., Martínez F., Gelpí E. Chromatographia 1982, 16(1):112. 10.1007/BF02258880.
8. Kotake C., Heffner T., Vosmer G., Seiden L. Pharmacol. Biochem. Behav. 1985, 22(1):85. 10.1016/0091-3057(85)90490-3.
9. Jussofie A., Lojewski J., Hiemke C. J. Liq. Chromatogr. 1993, 16(2):447. 10.1080/10826079308020923.
10. Mercolini L., Gerra G., Consorti M., Somaini L., Raggi M.A. Talanta 2009, 78(1):150. 10.1016/j.talanta.2008.10.049.
11. Yang L., Beal M.F. Methods Mol. Biol. 2011, 793:401. 10.1007/978-1-61779-328-8_27.
12. Nguyen A.T., Aerts T., Van Dam D., De Deyn P.P. J. Chromatogr. B 2010, 878(29):3003. 10.1016/j.jchromb.2010.09.019.
13. Hubert P., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Chiap P., Cohen N., Compagnon P.A., Dewé W., Feinberg M., Lallier M., Laurentie M., Mercier N., Muzard G., Nivet C., Valat L. J. Pharm. Biomed. Anal. 2004, 36(3):579. 10.1016/j.jpba.2004.07.027.
14. Hubert P., Nguyen-Huu J.J., Boulanger B., Chapuzet E., Chiap P., Cohen N., Compagnon P.A., Dewé W., Feinberg M., Lallier M., Laurentie M., Mercier N., Muzard G., Nivet C., Valat L., Rozet E. J. Pharm. Biomed. Anal. 2007, 45(1):70. 10.1016/j.jpba.2007.06.013.
15. Lewis D.A. Neuropsychopharmacology 2002, 26(2):143. 10.1038/S0893-133X(01)00393-1.
16. Stan A.D., Ghose S., Gao X.M., Roberts R.C., Lewis-Amezcua K., Hatanpaa K.J., Tamminga C.A. Brain Res. 2006, 1123(1):1. 10.1016/j.brainres.2006.09.025.
17. Corradini D., Katz E., Eksteen R., Schoenmakers P., Miller N. Handbook of HPLC (Chromatographic Science Series) 1998, CRC Press, Boca Raton, FL, USA.
18. Dong M.W. Modern HPLC for Practicing Scientists. 2006, Wiley-Blackwell, John Wiley & Sons, Hoboken, NJ, USA.
19. Shrivastava A., Gupta V.B. Chron. Young Sci. 2011, 2:21. 10.4103/2229-5186.79345.
20. Herregodts P., Ebinger G., Michotte Y. Neurosci. Lett. 1989, 98(3):321. 10.1016/0304-3940(89)90422-9.
21. Herregodts P., Ebinger G., Michotte Y. Brain Res. 1991, 542(2):300. 10.1016/0006-8993(91)91582-L.
22. Herregodts P., Bruyland M., De Keyser J., Solheid C., Michotte Y., Ebinger G. J. Neurol. Sci. 1989, 92(1):101. 10.1016/0022-510X(89)90179-2.
23. Nazarali AJ1, Reynolds G.P. Cell Mol. Neurobiol. 1992, 12(6):581. 10.1007/BF00711237.
24. Langlais P.J., Thal L., Hansen L., Galasko D., Alford M., Masliah E. Neurology 1993, 43(10):1927. 10.1212/WNL.43.10.1927.
25. Storga D., Vrecko K., Birkmayer J.G., Reibnegger G. Neurosci. Lett. 1996, 203(1):29. 10.1016/0304-3940(95)12256-7.
26. Vermeiren Y., Van Dam D., Aerts T., Engelborghs S., De Deyn P.P. J. Alzheimers Dis. 2014, [Epub ahead of print]. 10.3233/JAD-140309.
27. Y. Vermeiren, D. Van Dam, T. Aerts, S. Engelborghs, P.P. De Deyn, Monoaminergic neurotransmitter alterations in post-mortem brain regions of depressed and aggressive Alzheimer patients, Unpublished data/Revision submitted to Neurobiology of Aging.
28. A.D. Dekker, A.M.W. Coppus, Y. Vermeiren, T. Aerts, C.M. van Duijn, B.P. Kremer, P.J.W. Naudé, D. Van Dam, P.P. De Deyn, Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome, Unpublished data/Submitted to Journal of Alzheimer's.